| Nov 25 |
'Pharma Bro' Martin Shkreli Tells Investors To 'Short SAVA,' Stock Falls Over 80% After Phase 3 Update
|
| Nov 25 |
Cassava Sciences Stock Slides 84% as Alzheimer’s Trial Fails
|
| Nov 25 |
Cassava Sciences Alzheimer's Drug Fails To Hit Primary Goal In Pivotal Study, Pharma Halts Late-Stage Studies
|
| Nov 25 |
Cassava Stock Plunges as Alzheimer's Drug Fails Late-Stage Study
|
| Nov 25 |
Cassava Sciences Plummets 85% After Embattled Alzheimer's Drug Flops
|
| Nov 25 |
Cassava plummets 86% as simufilam phase 3 Alzheimer's trial misses endpoints
|
| Nov 25 |
Cassava Sciences Topline Phase 3 Data Did Not Meet Co-Primary Endpoints
|
| Nov 25 |
Cassava Sciences to Hold Corporate Update on November 25th
|
| Nov 18 |
Cassava taps Freda Nassif as chief commercial officer as simufilam Phase 3 readout nears
|
| Nov 18 |
Cassava Sciences Appoints Freda Nassif as Chief Commercial Officer
|
